Navigation Links
Santarus to Webcast Analyst Day and Investor Briefing Presentation on January 19
Date:1/19/2011

o the Investor Relations section of the company's website at www.santarus.comContact:Lippert/Heilshorn & AssociatesNarine Darbinyan310-691-7100About SantarusSantarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists.  The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.  

Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs:  ULTESA™ (budesonide MMX®) for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers' diarrhea.  In addition, Santarus plans to initiate a Phase I clinical study in the first half of 2011 with SAN-300, its anti-VLA-1 antibody, which the company expects to investigate for the treatment of rheumatoid arthritis.  

Santarus cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements.  The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans will be achieved.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Santarus' business, including, without limitation:  difficulties or delays in development, testing, manufacturing and marketing of, and obtaining and maintaining regulatory approvals for, Santarus' products; and other risks detailed in Santar
'/>"/>

SOURCE Santarus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Fourth Quarter and Year End 2010 Results
2. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
3. Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast
4. BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call
5. BD Announces Webcast of Annual Meeting of Shareholders
6. Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
7. Thoratec Presentation at J.P. Morgan Conference to Be Webcast
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
9. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
10. Cepheid to Webcast Upcoming Financial Presentation
11. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... According to a new market research report ... by Type (Invasive, Minimally Invasive, Non-Invasive), by End-User (Hospitals, ... Analysis & Global Forecast to 2019" , the global ... Million by 2019 from $887.8 Million in 2014, and ... during the forecast period. Browse 111 ...
(Date:3/5/2015)... Ascendis Pharma A/S, a clinical stage ... to address significant unmet medical needs, today announced ... 2015 conference being held at the San Diego ... Thursday, March 5, 2015 during the Pediatric Endocrinology—Clinical/Translational ... and are titled: TransCon ...
(Date:3/5/2015)... March 5, 2015  MGC Diagnostics Corporation (NASDAQ: ... company, today reported financial results for the first ... 2015 first quarter domestic equipment, supplies and accessories ... $3.7 million in the 2014 first quarter.  During ... or $338,000 in revenue, compared to 14 accounts, ...
Breaking Medicine Technology:Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 2Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 3Hemodynamic Monitoring Systems Market Worth $1,107.4 Million by 2019 4Ascendis Pharma to Present at ENDO 2015 2MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 2MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 3MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 4MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 5MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 6MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 7MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 8MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 9MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 10MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 11MGC Diagnostics Corporation Reports Fiscal 2015 First Quarter Results 12
(Date:3/5/2015)... 05, 2015 Central Nebraska Imaging (CNI) ... including the brand’s new logo and optimized website. ... practice’s modern approach to expert diagnostic imaging, centered on ... be built to be a resource for Nebraska patients ... automated forms, communication and referral functionality, video content and ...
(Date:3/5/2015)... 05, 2015 HomeCEUConnection.com is ... with extra savings on their nutrition CEUs. ... health and nutrition, HomeCEUConnection.com is offering 10% ... promo code, NUTRITION2015 . , High ... , HomeCEUConnection.com provides high-quality continuing education courses ...
(Date:3/5/2015)... Angeles, CA (PRWEB) March 05, 2015 ... article titled “Butt Augmentation, Labiaplasty on the Rise, Plastic ... reported by the American Society for Aesthetic Plastic ... Surgeons . Both groups reported a year-over-year doubling of ... of the physicians quoted in the article, this increase ...
(Date:3/5/2015)... In honor of National Drug Facts Week, ... and alcohol abuse in schools and communities across America, ... information on some of the dangers and statistics involved ... Institute on Drug Abuse, this annual promotion of the ... illusions that teens and young adults get from television, ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3
... neither improved nor deteriorated. There are 89 new cases, 2 deaths ... the number of dengue cases at the All India Institute of ... viral fever cases is also decreasing; however, the doctors cautioned that ... cases have come down but the outbreak isn't over," said Medical ...
... hopes of a team of eminent plastic surgeons led by ... waiting for the// final approval from The Royal Free hospital’s ... transplant which would involve the complete replacement of a disfigured ... ,Although the hospital had granted permission to ...
... in clinical use for decades, a small, sweet-tasting compound ... cure for epilepsy.// ,2-deoxy-glucose, or 2DG, has ... cancer imaging studies in humans. But now, researchers at ... blocks the onset of epileptic seizures in laboratory rats. ...
... must get its act together to check the perilous trend of ... suggested a cap on the// embryo, allowing only one embryo at ... the Human Fertilization and Embryology Authority (HFEA) has suggested that the ... two to one for patients who are not on the wrong ...
... Taxotere(docetaxel) from Sanofi-Aventis has been approved for its treatment ... showed that patients given chemotherapy with// Taxotere survived an ... to 8.3 months with standard drugs. ,The ... cisplatin and fluorouracil chemotherapy in locally advanced squamous cell ...
... gene therapy for Parkinson's disease has given the green signal ... symptoms for patients,// according to the reports of two groups ... and last week the researchers reported that each of the ... received some benefit and none had significant side effects. ...
Cached Medicine News:Health News:Commonplace Sugar Compound Silences Seizures 2Health News:Commonplace Sugar Compound Silences Seizures 3Health News:Gene therapy Beneficial in Parkinson's Disease 2Health News:Gene therapy Beneficial in Parkinson's Disease 3
... designed to travel a full 120 degrees, from ... wherever you release the rotating hand grip locking ... the handle with no need to ever go ... of system was designed to mimic the natural ...
Designed for Bariatric usage. Prevents arm or leg dropout during surgical procedures. Dimensions are 16"Lx10"H come in pairs. Optional gel pad available (BD2245)...
Designed to prevent arm or legs from dropouts during surgical procedures. Dimensions are 8"H x16"L. These come as pairs. Optional gel pads(BD2245)....
... Corporation offers a quality line ... to adults. Armboard covers are ... assuring easy cleaning while reducing ... Choose from three options: Disposable ...
Medicine Products: